

## MOLECULAR CANCER THERAPEUTICS

## TABLE OF CONTENTS

## HIGHLIGHTS

## 1957 Selected Articles from This Issue

## REVIEW

## 1959 Ion Channels and Their Role in the Pathophysiology of Gliomas

Takeshi Takayasu, Kaoru Kurisu, Yoshua Esquenazi, and Leomar Y. Ballester

## SMALL MOLECULE THERAPEUTICS

1970 Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity *In Vitro* and *In Vivo*

Yamini M. Ohol, Michael T. Sun, Gene Cutler, Paul R. Leger, Dennis X. Hu, Berenger Biannic, Payal Rana, Cynthia Cho, Scott Jacobson, Steve T. Wong, Jerick Sanchez, Niket Shah, Deepa Pookot, Betty Abraham, Kyle Young, Silpa Suthram, Lisa A. Marshall, Delia Bradford, Nathan Kozon, Xinpeng Han, Akinori Okano, Jack Maung, Christophe Colas, Jacob Schwarz, David Wustrow, Dirk G. Brockstedt, and Paul D. Kassner

1981 Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes *In Vitro* and *In Vivo*: Preclinical Studies as Guidance for Clinical Development and Trial Design

Hiroshi Sootome, Akihiro Miura, Norio Masuko, Takamasa Suzuki, Yoshihiro Uto, and Hiroshi Hirai

1992 The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of *NOXA*

Yohei Sugimoto, Yoshiki Katsumi, Tomoko Iehara, Daisuke Kaneda, Chihiro Tomoyasu, Kazutaka Ouchi, Hideki Yoshida, Mitsuru Miyachi, Shigeki Yagyu, Ken Kikuchi, Kunihiko Tsuchiya, Yasumichi Kuwahara, Toshiyuki Sakai, and Hajime Hosoi

2001 Targeting the Synthetic Vulnerability of *PTEN*-Deficient Glioblastoma Cells with *MCL1* Inhibitors

Chao Chen, Sichao Zhu, Xia Zhang, Tingting Zhou, Jing Gu, Yurong Xu, Quan Wan, Xiao Qi, Yezi Chai, Xiaorong Liu, Lukui Chen, Jie Yan, Yunfen Hua, and Fan Lin

## 2012 Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade

Eric T. Alexander, Kelsey Mariner, Julia Donnelly, Otto Phanstiel IV, and Susan K. Gilmour

## 2023 Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2

Qiaqia Li, Kilia Y. Liu, Qipeng Liu, Guangyu Wang, Weihua Jiang, Qingshu Meng, Yang Yi, Yongyong Yang, Rui Wang, Sen Zhu, Chao Li, Longxiang Wu, Dongyu Zhao, Lin Yan, Lili Zhang, Jung-Sun Kim, Xiongbing Zu, Anthony J. Kozielski, Wei Qian, Jenny C. Chang, Akash Patnaik, Kaifu Chen, and Qi Cao

2034 Targeted Radionuclide Therapy in Patient-Derived Xenografts Using <sup>177</sup>Lu-EB-RGD

Liang Zhao, Haojun Chen, Zhide Guo, Kaili Fu, Lanling Yao, Li Fu, Weixi Guo, Xuejun Wen, Orit Jacobson, Xianzhong Zhang, Long Sun, Hua Wu, Qin Lin, and Xiaoyuan Chen

## LARGE MOLECULE THERAPEUTICS

## 2044 Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trophocytosis

**A C** Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendekci, Marilda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre, and Sheri L. Moores

## 2057 Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients

Eugene S. Bah, Rebecca A. Nace, Kah Whye Peng, Miguel Ángel Muñoz-Alía, and Stephen J. Russell

# TABLE OF CONTENTS

- 2068** **PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers**  
Edmund I. Graziani, Matthew Sung, Dangshe Ma, Bitha Narayanan, Kimberly Marquette, Sujiet Puthenveetil, L. Nathan Tumey, Jack Bikker, Jeffrey Casavant, Eric M. Bennett, Manoj B. Charati, Jonathon Golas, Christine Hosselet, Cynthia M. Rohde, George Hu, Magali Guffroy, Hadi Falahatpisheh, Martin Finkelstein, Tracey Clark, Frank Barletta, Lioudmila Tchistiakova, Judy Lucas, Edward Rosfjord, Frank Loganzo, Christopher J. O'Donnell, Hans-Peter Gerber, and Puja Sapra
- 2079** **Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody-Drug Conjugate in Patient-derived Xenografts**  
**A C** Adnan O. Abu-Yousif, Donna Cvet, Melissa Gallery, Bret M. Bannerman, Michelle L. Ganno, Michael D. Smith, Katharine C. Lai, Thomas A. Keating, Bradley Stringer, Afrand Kamali, Kurt Eng, Secil Koseoglu, Andy Zhu, Cindy Q. Xia, Melissa Saylor Landen, Maria Borland, Robbie Robertson, Jayaprakasam Bolleddula, Mark G. Qian, Jennifer Fretland, and O. Petter Veiby
- 2089** **Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies**  
Haihui Lu, Ryan D. Molony, Dongshu Chen, Sunyoung Jang, Babette Wolf, Stefan Ewert, Meghan Flaherty, Fangmin Xu, Sinan Isim, Yeonju Shim, Christina Dornelas, Nicole Balke, Xavier Charles Leber, Meike Scharenberg, Johanna Koelln, Eugene Choi, Rebecca Ward, Jennifer Johnson, Thomas Calzascia, Isabelle Isnardi, Juliet A. Williams, Pieter L. Lindenbergh, Niels W.C.J. van de Donk, Tuna Mutis, Heather Huet, Emma Lees, and Matthew J. Meyer
- 2105** **Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody**  
Amir A. Al-Khami, Sawsan Youssef, Yasmina Abdiche, HoangKim Nguyen, Joyce Chou, Christopher R. Kimberlin, Sherman M. Chin, Cris Kamperschroer, Bart Jessen, Brent Kern, Natalija Budimir, Christopher P. Dillon, Allison Xu, Jerry D. Clark, Jeffrey Chou, Eugenia Kraynov, Arvind Rajpal, John C. Lin, and Shahram Salek-Ardakani
- 2117** **Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate**  
Mark G. Anderson, Hugh D. Falls, Michael J. Mitten, Anatol Oleksijew, Kedar S. Vaidya, Erwin R. Boghaert, Wenqing Gao, Joann P. Palma, Diana Cao, Puey-Ling Chia, Thomas John, Hui K. Gan, Andrew M. Scott, and Edward B. Reilly
- 2126** **Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism**  
**A C** Marije B. Overdijk, Kristin Strumane, Frank J. Beurskens, Antonio Ortiz Buijsse, Claudine Vermot-Desroches, Boris S. Vuillermoz, Thessa Kroes, Bart de Jong, Naomi Hoevenaars, Richard G. Hibbert, Andreas Lingnau, Ulf Forssmann, Janine Schuurman, Paul W.H.I. Parren, Rob N. de Jong, and Esther C.W. Breij
- COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS**
- 2139** **High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers**  
**A C** Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Sharabi, Shumei Kato, and Razelle Kurzrock
- 2146** **Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib**  
Yingmiao Liu, Jing Lyu, Kirsten Bell Burdett, Alexander B. Sibley, Ace J. Hatch, Mark D. Starr, John C. Brady, Kelli Hammond, Federica Marmorino, Daniele Rossini, Richard M. Goldberg, Alfredo Falcone, Chiara Cremolini, Kouros Owzar, Anastasia Ivanova, Dominic T. Moore, Michael S. Lee, Hanna K. Sanoff, Federico Innocenti, and Andrew B. Nixon
- 2155** **Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors**  
E. Gabriela Chiorean, Susan M. Perkins, R. Matthew Strother, Anne Younger, Jennifer M. Funke, Safi G. Shahda, Noah M. Hahn, Kumar Sandrasegaran, David R. Jones, Todd C. Skaar, Bryan P. Schneider, Christopher J. Sweeney, and Daniela E. Matei
- CANCER BIOLOGY AND TRANSLATIONAL STUDIES**
- 2163** **Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy**  
Christian K. Werner, Uchechi J. Nna, Hanshi Sun, Kari Wilder-Romans, Joseph Dresser, Ayesha U. Kothari, Weihua Zhou, Yangyang Yao, Arvind Rao, Stefanie Stallard, Carl Koschmann, Tarik Bor, Waldemar Debinski, Alexander M. Hegedus, Meredith A. Morgan, Sriram Venneti, Edwina Baskin-Bey, Daniel E. Spratt, Howard Colman, Jann N. Sarkaria, Arul M. Chinnaiyan, Joel R. Eisner, Corey Speers, Theodore S. Lawrence, Roy E. Strowd, and Daniel R. Wahl

# TABLE OF CONTENTS

**2175**     **Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy**

Masahiro Shibata, Akira Ooki, Yoshikuni Inokawa, Pritam Sadhukhan, M. Talha Ugurlu, Evgeny Izumchenko, Enrico Munari, Giuseppe Bogina, Charles M. Rudin, Edward Gabrielson, Anju Singh, and Mohammad O. Hoque

**2186**     **The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma**

Florencia Rago, GiNell Elliott, Ailing Li, Kathleen Sprouffske, Grainne Kerr, Aurore Desplat, Dorothee Abramowski, Julie T. Chen, Ali Farsidjani, Kay X. Xiang, Geoffrey Bushold, Yun Feng, Matthew D. Shirley, Anka Bric, Anthony Vattay, Henrik Möbitz, Katsumasa Nakajima, Christopher D. Adair, Simon Mathieu, Rukundo Ntaganda, Troy Smith, Julien P.N. Papillon, Audrey Kauffmann, David A. Ruddy, Hyo-eun C. Bhang, Deborah Castelletti, and Zainab Jagani

**2196**     **Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy**

Xiao-Min Wang, Pan Gu, Leorey Saligan, Michael Iadarola, Stanley Sau Ching Wong, Lian Kah Ti, and Chi Wai Cheung

**2210**     **Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer**

**AC**

Yoshihisa Kawai, Kenjiro Imada, Shusuke Akamatsu, Fan Zhang, Roland Seiler, Tetsutaro Hayashi, Jeffrey Leong, Eliana Beraldi, Neetu Saxena, Alexander Kretschmer, Htoo Zarni Oo, Alberto Contreras-Sanz, Hideyasu Matsuyama, Dong Lin, Ladan Fazli, Colin C. Collins, Alexander W. Wyatt, Peter C. Black, and Martin E. Gleave

## MODELS AND TECHNOLOGIES

**2221**     **Hypomorphic mTOR Downregulates CDK6 and Delays Thymic Pre-T LBL Tumorigenesis**


Joy M. Gary, John K. Simmons, Jinfei Xu, Shuling Zhang, Tyler J. Peat, Nicholas Watson, Benjamin J. Gamache, Ke Zhang, Alexander L. Kovalchuk, Aleksandra M. Michalowski, Jin-Qiu Chen, Tuddow Thaiwong, Matti Kiupel, Snehal Gaikwad, Maudeline Etienne, R. Mark Simpson, Wendy Dubois, Joseph R. Testa, and Beverly A. Mock

**AC** icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

In this issue of *Molecular Cancer Therapeutics*, Vijayaraghavan and colleagues outline the mechanism of an anti-EGFR/anti-cMET bispecific antibody, Amivantamab. The anti-tumor efficacy of amivantamab required the Fc-dependent trogocytosis, pictured on our cover. In trogocytosis, macrophages (shown in green) acquired fragments of opsonized tumor cell membranes (shown in orange). Read the full article on page 2044.



# Molecular Cancer Therapeutics

**19 (10)**

*Mol Cancer Ther* 2020;19:1957-2232.

**Updated version** Access the most recent version of this article at:  
<http://mct.aacrjournals.org/content/19/10>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/19/10>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.